Last reviewed 2026-04-20 · How we verify

CPX-351 (cpx-351)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Febrile Neutropenia
• Nausea
• Constipation
• Diarrhoea
• Oedema Peripheral
• Fatigue
• Headache
• Epistaxis
• Cough
• Decreased Appetite
• Rash
• Vomiting

Key clinical trials

• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
• Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (PHASE2)
• Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
• CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics (PHASE2)
• Phase IB/II of CPX-351 for Relapse Prevention in AML (PHASE1, PHASE2)
• Tazemetostat and Palbociclib With CPX-351for R/R AML (PHASE1)
• Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
• CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CPX-351 CI brief — competitive landscape report
• CPX-351 updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI